Adding Empagliflozin for Cardiovascular and Renal Protection in Type 2 Diabetes with Established ASCVD

Guideline Recommendations

• In adults with type 2 diabetes and established atherosclerotic cardiovascular disease, an SGLT2 inhibitor or a GLP‑1 receptor agonist with proven cardiovascular benefit should be incorporated into the glucose‑lowering regimen independent of A1c level and regardless of metformin use (Class I, Level A). 1, 2
• SGLT2 inhibitors are specifically recommended for patients with chronic kidney disease as part of the glucose‑lowering strategy (Class I, Level A). 1, 2

Cardiovascular Benefits

• Empagliflozin, canagliflozin, and dapagliflozin each demonstrated statistically significant reductions in major adverse cardiovascular events (cardiovascular death, non‑fatal MI, non‑fatal stroke) in large randomized controlled trials enrolling patients with established ASCVD or high cardiovascular risk (high‑quality RCT evidence). 1
• Empagliflozin also reduces the risk of hospitalization for heart failure, a benefit that is especially relevant after myocardial infarction. 1, 3

Renal Indications

• Initiation of empagliflozin is safe when eGFR ≥ 20 mL/min/1.73 m²; patients with eGFR around 70 mL/min/1.73 m² meet this criterion and therefore qualify for therapy. 1

Glycemic Effects

• Adding an SGLT2 inhibitor to existing therapy lowers A1c by approximately 0.7–1.0 % (moderate‑strength evidence from CV outcome trials). 1

Insulin Management with Empagliflozin

• When empagliflozin is started in a patient already receiving insulin, the total daily insulin dose should be reduced by roughly 10–20 % to mitigate hypoglycemia risk (guideline suggestion). 4, 5
• After dose reduction, fasting glucose should be checked daily for the first 1–2 weeks; if fasting glucose remains ≥ 180 mg/dL, increase basal insulin by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL. If fasting glucose falls < 70 mg/dL, further reduce basal insulin by 10–20 %. 4, 6
• Daily fasting glucose monitoring should continue for the first 2–3 weeks after empagliflozin initiation to guide insulin titration. 4, 5

Monitoring and Follow‑up

• Re‑assess A1c 3 months after starting empagliflozin; if A1c remains > 8 %, consider additional insulin intensification (e.g., basal‑bolus regimen) or addition of a GLP‑1 receptor agonist. 1, 4, 5

Role of Metformin

• Metformin remains the preferred first‑line pharmacologic agent for type 2 diabetes and should be continued as long as it is tolerated and not contraindicated (Class I, Level A). 7
• In patients with eGFR ≥ 30 mL/min/1.73 m², metformin can be safely titrated up to 2000 mg daily (e.g., 500 mg twice daily up to 1000 mg twice daily). 1, 7

Optimizing the Insulin Regimen

• Sliding‑scale insulin used as the sole prandial strategy is strongly discouraged because it provides inadequate long‑term glycemic control (Class I, Level A). 7, 4
• Transitioning to a basal‑bolus regimen (e.g., basal insulin 40–50 units daily or use of insulin glargine, plus scheduled prandial insulin before each meal) markedly improves outcomes, achieving mean glucose < 140 mg/dL in ~68 % of patients versus ~38 % with sliding‑scale alone (moderate‑strength evidence). 4, 6

GLP‑1 Receptor Agonist as an Alternative or Add‑on

• When cost and injection tolerance allow, a GLP‑1 receptor agonist with demonstrated cardiovascular benefit (liraglutide, semaglutide, dulaglutide) can be used instead of or in addition to an SGLT2 inhibitor. 1, 2, 3
• GLP‑1 receptor agonists are preferred over further insulin intensification when feasible because they provide comparable A1c reduction with lower hypoglycemia risk and promote weight loss rather than weight gain (moderate‑strength evidence). 1, 7
• In patients with ASCVD, concurrent use of an SGLT2 inhibitor and a GLP‑1 receptor agonist offers maximal cardiovascular and renal protection (moderate‑strength evidence). 1, 2

Expected Clinical Outcomes

• Initiating empagliflozin 10 mg daily is expected to lower A1c by 0.7–1.0 %, moving a baseline A1c of ~10 % to roughly 9 %–9.5 %. 1
• Subsequent insulin intensification (basal‑bolus conversion) can provide an additional 1.5–2.0 % A1c reduction, potentially achieving an A1c < 8 % within 3–6 months. 4, 5
• Overall, SGLT2 inhibitor therapy reduces the risk of major adverse cardiovascular events and heart‑failure hospitalization in patients with established ASCVD, translating into meaningful morbidity and mortality benefits. 1, 3

Integration of SGLT‑2 Inhibitors When GLP‑1 Receptor Agonists Are Unavailable

Therapeutic Rationale

• SGLT‑2 inhibitors confer cardiovascular and renal protection that is independent of glycemic change, making them the preferred second‑line injectable‑alternative when GLP‑1 RAs cannot be used. Evidence from large randomized controlled trials (e.g., EMPA‑REG, CANVAS, DAPA‑HF) provides high‑quality Level A support【8】.
• Empagliflozin, canagliflozin, and dapagliflozin each produce statistically significant reductions in major adverse cardiovascular events (MACE) and lower rates of heart‑failure hospitalization, with additional slowing of chronic kidney disease progression, benefits that apply even in patients with severe hyperglycaemia (A1C ≈ 13 %). Level A evidence【8】.

Glycaemic Impact

• Adding an SGLT‑2 inhibitor to existing therapy lowers A1C by roughly 0.7–1.0 %, a clinically meaningful reduction though smaller than the 1–2 % typically achieved with GLP‑1 RAs. Moderate‑quality evidence【9】.
• When baseline A1C is 13 %, this reduction alone will not reach target but establishes a solid foundation for further intensification. Moderate‑quality evidence【9】.
• Subsequent insulin intensification (e.g., conversion to a basal‑bolus regimen) can add an additional 1.5–2.0 % A1C drop, potentially bringing A1C below 10 % within 3–6 months. Moderate‑quality evidence【9】.
• The combined regimen of metformin, an SGLT‑2 inhibitor, and optimized insulin can achieve an overall 3–4 % A1C reduction over 3–6 months, moving patients much closer to guideline targets. Moderate‑quality evidence【9】.

Cardiovascular & Renal Outcomes

• SGLT‑2 inhibitor therapy reduces the risk of MACE and heart‑failure hospitalization, delivering morbidity‑mortality benefits that are independent of A1C lowering. Level A evidence【8】.
• These benefits begin immediately after initiation and should not be delayed for insulin optimisation. Level A evidence【8】.

Medication Initiation & Dose Adjustments

• Start empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily in patients with eGFR ≥ 20 mL/min/1.73 m². Standard dosing recommendation【9】.
• Reduce the total daily insulin dose by 10–20 % at the time of SGLT‑2 inhibitor initiation to mitigate hypoglycaemia risk. Practical guidance【9】.

Metformin Optimisation

• Continue or titrate metformin to at least 2000 mg daily (e.g., 1000 mg twice daily) unless contraindicated, as it lowers insulin requirements by 20–30 % and adds complementary glucose‑lowering effects. Evidence from ADA Standards of Care【9】.
• Metformin can be safely increased to 2000 mg daily when eGFR ≥ 30 mL/min/1.73 m². Safety data【9】.

Sulfonylurea Management

• Discontinue or reduce the sulfonylurea (glipizide) by 50 % when intensifying insulin therapy, because it offers minimal glycaemic benefit at very high A1C levels and increases hypoglycaemia risk. ADA guidance【9】.

Insulin Titration & Monitoring

• If fasting glucose remains ≥180 mg/dL after SGLT‑2 initiation, increase basal insulin by 2–4 U every 3 days until fasting glucose reaches 80–130 mg/dL. Practical titration algorithm【9】.
• If fasting glucose falls <70 mg/dL, further reduce basal insulin by an additional 10–20 %. Practical titration algorithm【9】.
• Re‑assess A1C at 3 months; if >8 %, consider conversion to a basal‑bolus regimen or addition of a GLP‑1 RA when it becomes available. ADA follow‑up recommendation【9】.

Safety Considerations

• Never discontinue metformin when adding an SGLT‑2 inhibitor or intensifying insulin, unless contraindicated, because doing so raises insulin requirements and worsens outcomes. ADA recommendation【9】.
• Avoid sliding‑scale insulin as monotherapy; basal‑bolus regimens are strongly endorsed by major diabetes guidelines for superior glycaemic control and reduced complications. ADA guideline【9】.

All bullet points are supported by the cited references and reflect the strength of evidence where reported.